Skip to main content
Clinical Trials/NCT04738591
NCT04738591
Completed
N/A

Feasibility Study Through a Phase II Randomized Clinical Trial of an Intervention Based on Short Message System (SMS) to Promote Adherence to Antidiabetic Medication and Healthy Lifestyles in Patients With Type 2 Diabetes Mellitus

Fundació d'investigació Sanitària de les Illes Balears1 site in 1 country207 target enrollmentDecember 30, 2020

Overview

Phase
N/A
Intervention
Not specified
Conditions
Diabetes Mellitus, Type 2
Sponsor
Fundació d'investigació Sanitària de les Illes Balears
Enrollment
207
Locations
1
Primary Endpoint
Glycated Hemoglobin (HbA1C)
Status
Completed
Last Updated
last year

Overview

Brief Summary

This study aims at evaluating the feasibility of an intervention based on the use of a mobile-device based system delivering automated, tailored brief text messages to offer support for medicine use and lifestyle recommendations alongside usual care to people with type 2 diabetes.

Detailed Description

A list of patients registered in primary care centers of the Balearic Islands and potentially meeting the eligibility criteria will be obtained from electronic health records (EHRs). A research assistant will contact the potential participants via phone to invite them to the study and confirm eligibility. All eligible participants will complete informed consent followed by baseline assessment over the phone before randomization. Participants will be randomly allocated using a computer-generated randomization sequence. All participants will continue with their usual diabetes care including all medical visits, tests, and diabetes support programs throughout the study. In addition, the intervention group will receive the text messaging intervention. Control participants will receive usual care only. After three months of follow-up, all participants will complete post-intervention assessments via phone interview. Data on glycemic control (HbA1c) at baseline and post-intervention will be extracted from EHRs, as according to the protocol used for primary care providers in the Balearic Islands, patients with poor glycemic control (HbA1c \>8% ) must request an HbA1c determination every six months. Results of the most recent determination will be extracted from electronic medical records. For those patients with no recorded HbA1c within the previous three months, the research assistant will contact the primary care center and the patient to arrange blood test analyses.

Registry
clinicaltrials.gov
Start Date
December 30, 2020
End Date
June 28, 2021
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Fundació d'investigació Sanitària de les Illes Balears
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients registered in the Public Health Service of the Balearic Islands
  • With type 2 diabetes
  • At least one prescription of an oral glucose-lowering drug
  • With results of HbA1C\>8% from 3 months prior to recruitment.

Exclusion Criteria

  • Younger than 18 years old
  • With insulin treatment.

Outcomes

Primary Outcomes

Glycated Hemoglobin (HbA1C)

Time Frame: Baseline and post-intervention at 3 months

HbA1c was extracted as percentage which is calculated following the standard formulae \[HbA1c(%)=(HbA1c(mmol/mol)+23.5)/10.93\] based on its concentration in blood samples. It identifies average plasma glucose concentration.

Secondary Outcomes

  • Number of Participants Classified as Adherent Based on Self-reporteAdherence to Antidiabetic Medication (7 Items ad Hoc Questionnaire)(Baseline and post-intervention at 3 months)
  • Enrolment or Recruitment Rate(Baseline)
  • Retention Rate(3 months)

Study Sites (1)

Loading locations...

Similar Trials